In a recently published study, Korean scientists announced they are currently testing a treatment that has shown promise in fighting mesothelioma. Manumycin A, an antibiotic derived from the bacterium Streptomyces parvulus, has been shown to reduce certain tumors in mice during lab trials. Manumycin A exhibits anticancer properties and may potentially be a promising treatment for one of the deadliest cancers, mesothelioma. The antibiotic seems to interrupt the cellular processes that lead to cancer.
Mesothelioma is a rare, but deadly cancer, typically caused by short and long term exposure to asbestos. When we breathe or swallow asbestos mineral fibers, they become trapped in our lungs, heart, or stomach. Over time these fibers alter or scar body tissue, often leading to cancer. The latency period for mesothelioma to develop is several years, leading to diagnoses for mesothelioma occurring decades after asbestos exposure. The average latency period for men is around 48 years; for women, around 53.
While there is hope for the use of the Manumycin A antibiotic in treating mesothelioma, the general public will not have access to it for quite some time outside of clinical trials. In the meantime, victims face serious medical and financial challenges as they battle cancer
According to the National Institutes of Health, approximately 11 million people were exposed to asbestos from 1940 – 1978. Current treatment for mesothelioma consists of surgery, radiation, and chemotherapy. The possibility of a less-invasive, more effective treatment option like this antibiotic is exciting. The counsel of a qualified Philadelphia mesothelioma lawyer can protect the financial resources of cancer victims so they can focus on fighting this disease.
While the Manumycin A antibiotic treatment looks encouraging, millions of victims will battle mesothelioma until it becomes available to the public. Victims of asbestos-related cancer know the disease could have been prevented. Companies that were aware of the dangers of asbestos but exposed employees to it should be held accountable.
Brookman, Rosenberg, Brown & Sandler offer knowledgeable and compassionate in asbestos-related claims in Pennsylvania, and New Jersey. Call our Philadelphia office at 215-569-4000 or contact us online to discuss your case today. Our dedicated team of Philadelphia mesothelioma lawyers can fight for the compensation you deserve.